16 September 2026 editorial review · Item
Vertex VX-264 (device-encapsulated stem-cell islets): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: corrected/updated. Current item
lastReviewed: 2026-09-16. - Claim check: VX-264 was discontinued after insufficient C-peptide production. Active registry follow-up does not restart the programme. Removed speculative hypoxia/fibrosis causation and claims that safety was proved; sponsor-reported early tolerability is not a definitive safety conclusion.
- Registry NCT05791201: ACTIVE_NOT_RECRUITING; updated 2026-09-10; enrollment 7 (ACTUAL); primary completion 2027-03-12 (ESTIMATED); results not posted in retrieved record.
- Primary publication/regulatory sources checked or consulted: NEJMoa2506549; db25-0037.